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Abstract
Background: We reported previously that the cardiac troponin I (cTnI) promoter drives cardiac-
specific expression of reporter genes in cardiac muscle cells and in transgenic mice, and that
disruption of GATA elements inactivates the cTnI promoter in cultured cardiomyocytes. We have
now examined the role of cTnI promoter GATA elements in skeletal muscle cells.
Results: Mutation or deletion of GATA elements induces a strong transcriptional activation of the
cTnI promoter in regenerating skeletal muscle and in cultured skeletal muscle cells. Electrophoretic
mobility shift assays show that proteins present in nuclear extracts of C2C12 muscle cells bind the
GATA motifs present in the cTnI promoter. However, GATA protein complex formation is
neither reduced nor supershifted by antibodies specific for GATA-2, -3 and -4, the only GATA
transcripts present in muscle cells.
Conclusion: These findings indicate that the cTnI gene promoter is repressed in skeletal muscle
cells by GATA-like factors and open the way to further studies aimed at identifying these factors.
Background
Establishment and maintenance of cell specification
involves both activating and repressive mechanisms.
While positive gene regulation by tissue-specific transcrip-
tion factors is well established, the role of negatively act-
ing transcription factors has been comparatively less
investigated. For example, cardiac and skeletal muscle
cells are known to co-express a large number of muscle
genes, but the regulatory regions in the gene promoters
differ between the two cell types. Both common regula-
tory factors, such as MEF2, and cardiac- or skeletal muscle-
specific transcription factors, such as GATA-4 and MyoD,
respectively, have been implicated as tissue-specific activa-
tors of muscle gene expression. A few studies have
described the repression of muscle gene as a mechanism
that control cardiac muscle restricted gene expression.
Mutations in the HF-3 element (TAACCTTGAAGGC) of
the ventricular myosin light chain 2 promoter leads to
marked up-regulation of promoter activity in skeletal
muscles of transgenic mice [1]. The transcription factor
Nishéd, which binds to a GAAG/CTTC sequence, appears
to account for the repression of the chicken cardiac
myosin light chain 2 in skeletal muscle [2].
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The cardiac troponin I (cTnI) gene encodes for the cardiac
specific inhibitory subunit of the troponin complex, one
of the few sarcomeric proteins that is expressed in cardiac
but not skeletal muscle [3]. We have reported previously
that this specificity is controlled by the proximal 5'-flank-
ing region of the promoter (-230/+16), which drives car-
diac-specific expression both in cultured cardiac cells, in
terminally differentiated cardiac muscle cell in vivo and in
transgenic mice [4]. Different types of transcription fac-
tors control the expression of the cTnI promoter in cardiac
muscle cells. Among these, three GATA elements, that are
targets of GATA-4 transcription factor, are required for
promoter activity, as disruption of these elements inacti-
vates the cTnI promoter in cultured cardiomyocytes [4].
Here we report that, surprisingly, the activity of the cTnI
promoter is markedly increased in skeletal muscle by
mutation or deletion of GATA sites. Nuclear extracts of
muscle cells contain proteins distinct from canonical
GATA factors that form specific complexes with the GATA
elements present in the cTnI promoter. These findings
point to a novel mechanism of repression of cardiac gene
promoters in skeletal muscle involving GATA sites.
Results
cTnI promoter activity is increased by disruption of GATA 
elements in skeletal muscle cells
The proximal promoter of the cTnI gene (-230/+16) is suf-
ficient to drive cardiac-specific expression of reporter
genes both in cultured cardiomyocytes and in transgenic
mice [4]. Promoter analysis showed that three types of
regulatory elements are required for optimal gene activa-
tion. These include three GA-rich elements binding Sp1
and located betweeen -175 and -133, an A/T-rich motif
binding MEF2 and Oct1 and lying at position -36, and
three GATA elements, two of which are closely associated
between -67 and -57 of the promoter whereas the third is
located just upstream of the transcriptional start site.
Deletion and mutation analyses showed that mutation of
GATA elements inactivated the cTnI promoter in cultured
cardiomyocytes [4].
We have now performed cTnI promoter analyses in skele-
tal muscle, a tissue that does not express cTnI [3]. For
these experiments we used the regenerating rat soleus
muscle, a model that allows efficient gene transfer [5] and
can be used for promoter analyses in vivo [6-8]. As shown
in Figure 1, in regenerating muscle the -230 cTnI/CAT pro-
moter/reporter construct is expressed at very low levels,
similar to the levels seen in non muscle cells [4]. The activ-
ity of the promoter is neither affected by deletion of the
three Sp1 binding elements located between -145 and -
127 [4] nor by mutation of the A/T-rich motif. In contrast,
mutation of the proximal GATA element (GATA →
CACA) surprisingly leads to 5-fold increase in promoter
activity and an even greater effect is observed by mutating
the more distal tandem GATA elements or all three GATA
motifs (13- and 15-fold increase in promoter activity,
respectively). To rule out the possibility that this effect is
due to generation of new binding sites, we produced two
additional mutants: in the first we deleted the two
upstream GATA elements in the context of the -230 pro-
moter, in the other we made a different mutation in all
three GATA sites (GATA → GCCA). As shown in Fig. 1,
promoter activity is also markedly increased in the deleted
mutant and in the construct with the GATA → GCCA
mutation. The activation of the promoter cannot therefore
be due to generation of new binding sites for activating
transcription factors, but must result from the lack of a
repressive effect of factors binding to these elements.
Next we asked whether the effect of GATA mutations in
the cTnI promoter is also observed in cultured skeletal
The cTnI promoter is activated by mutation or deletion of  GATA sites in skeletal muscle in vivo Figure 1
The cTnI promoter is activated by mutation or dele-
tion of GATA sites in skeletal muscle in vivo. Transfec-
tion experiments of cTnI-CAT constructs in regenerating rat 
soleus muscles. The -230/+16 cTnI promoter and different 
mutants are schematically represented on the left, the three 
GATA site being indicated with squares and the A/T rich ele-
ment with an oval. CAT activities in transfected muscles are 
shown on the right. The following mutants were examined 
(top to bottom): -145 and -127 deletion mutants, leading to 
the deletion of two of three or all three GA-rich sequences, 
respectively; mutation of the A/T-rich sequence (filled oval); 
GATA → CACA mutation of the proximal GATA site 
(crossed square); GATA → CACA mutation of the two dis-
tal GATA sites (two crossed squares); GATA → CACA 
mutation of all three GATA sites (three crossed squares); 
deletion of the two distal GATA sites; GATA → GCCA 
mutation of all three GATA sites (filled squares). Note that 
deletion/mutation of GATA sites leads to increased activity 
of the cTnI promoter, up to levels even higher than the SV40 
promoter. Values (means ± S.E.) are expressed as fold 
increase in CAT activity over the promoterless construct. 
Each construct was tested in 4 to 8 independent experi-
ments.
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muscle cells. Primary cultures from newborn rat heart and
skeletal muscle were transfected with wild-type cTnI pro-
moter and mutated constructs. As shown in Fig. 2, pro-
moter activity was decreased in cardiac but was markedly
increased in skeletal muscle cells by mutations of GATA
elements. Similar effects were observed with C2C12 cells
(not shown).
cTnI GATA binding activity is present in nuclear extracts of 
skeletal muscle cells
These results suggest that factors binding to GATA ele-
ments are present in skeletal muscle cells and are required
for repressing the cTnI promoter in these cells. To support
this interpretation, we performed electrophoretic mobil-
ity shift assays (EMSA) with C2C12 muscle cell nuclear
extracts (Fig. 3). Using a DNA probe spanning the two dis-
tal GATA sites of the cTnI promoter and nuclear extracts
from differentiated C2C12 cells, we identified a major
retarded complex (lane 1). The formation of this complex
was prevented by self-competition (lane 2) and by GATA
sequences from the B-type natriuretic peptide (BNP) pro-
moter (lane 7, 8). In contrast, competition with 50-fold or
100-fold molar excess of double stranded oligonucle-
otides containing the same mutations in the GATA sites
used for promoter analyses (lane 3–6) did not remove the
complex. Therefore, a specific GATA binding activity is
present in nuclear extracts of C2C12 muscle cells.
GATA-2, -3 and -4, but not GATA-1, -5 and -6 transcripts 
are present in skeletal muscle cells
GATA transcription factors have been grouped in two sub-
families based on their expression pattern: GATA-1, -2 and
-3 genes are mainly expressed in hematopoietic cells,
while GATA-4, -5 and -6 are expressed in various meso-
derm- and endoderm-derived tissues, including heart and
gut [9-11]. There is no report on the expression of GATA
factors in skeletal muscle, except for GATA-2 and -3.
GATA-3 transcripts are expressed in the somites at E10,
The cTnI promoter GATA motifs are target for a protein  complex in nuclear extracts from C2C12 muscle cells Figure 3
The cTnI promoter GATA motifs are target for a 
protein complex in nuclear extracts from C2C12 
muscle cells. A 32P-labeled probe encompassing the two 
distal GATA elements in the cTnI promoter (see Table 1) 
shows a major retarded complex (arrow) when incubated 
with nuclear extracts from cultured C2C12 muscle cells 
(lane 1). For competition assays, the following non-radioac-
tive competitors were added to the reaction mixture at 50- 
and 100- molar excess prior to the addition of the probe: self 
competitor (lane 2, 100-fold molar excess), CACA mutated 
cTnI GATA motifs (lanes 3 and 4), GCCA mutated cTnI 
GATA motifs (lanes 5 and 6), and a GATA sequence from 
the BNP promoter (lanes 7 and 8). The formation of the 
complex is prevented by the cTnI and BNP GATA sequences 
but is unaffected by the mutated cTnI GATA sequences.
Self
1     2     3     4    5     6     7     8
Probe cTnI GATA
CACA GCCA BNP
The cTnI promoter is activated by mutation or deletion of  GATA sites in skeletal muscle cells in vitro Figure 2
The cTnI promoter is activated by mutation or dele-
tion of GATA sites in skeletal muscle cells in vitro. 
Transfection experiments of cTnI-CAT constructs in cul-
tured primary cardiomyocytes (grey bars) and skeletal mus-
cle cells (black bars). Schematic drawings of constructs are as 
in Fig. 1. Note that mutation of GATA sites leads to 
decreased promoter activity in cardiomyocytes but increased 
activity in skeletal muscle cells. Values (means ± S.E.) are 
expressed as fold increase in normalized CAT activity over 
the promoterless construct. Each construct was tested in 4 
to 5 independent experiments.
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and GATA-3 promoter can also drive lacZ expression in
somites at E11.5 [12]. GATA-2 transcript and protein are
induced by IGF-1 in skeletal muscle fibers undergoing
hypertrophy both in vitro and in vivo [13-15]. We investi-
gated the expression of GATA factors by RT-PCR in C2C12
muscle cells and detected the presence of GATA-2, -3 and
-4 but not GATA-1, -5 and -6 transcripts (Fig. 4A). Quan-
titative real-time PCR showed that GATA-4 mRNA is rela-
tively more abundant than GATA-3 and GATA-2 in muscle
cells (Fig. 4B).
GATA-2, -3 and -4 proteins are not responsible for cTnI 
GATA binding activity in skeletal muscle cells
Western blotting analysis was performed to determine
whether GATA-2, -3 and -4, which are detected in skeletal
muscle cells at the transcript level, are also present at the
protein level. However, with the exception of a very faint
band observed for GATA-2, these GATA factors were not
detected in blots from C2C12 myotubes incubated with
specific antibodies (Fig. 5). Gel shift assays were also used
to determine whether GATA-2, -3 and -4 proteins are in
fact present in skeletal muscle cell nuclear extracts and
bind GATA elements of the cTnI promoter. As shown in
Fig. 6, the GATA-2 antibody, that partially inhibits the for-
mation of the specific complex in control Jurkat nuclear
extract (lane 1, 2), does not significantly change the pat-
tern of gel retardation with C2C12 extract (lane 4, 5). In
the presence of the GATA-3 antibody, a clear supershift is
observed with Jurkat nuclear extracts (lane 3), whereas the
pattern of gel retardation is unchanged with C2C12
extract (lane 6). Finally, a GATA-4 antibody produced a
strong supershift with cardiac muscle cell nuclear extract
(lane 7, 8) but not with C2C12 cell extract (lane 9, 10).
Discussion
The results reported here indicate that the cTnI gene pro-
moter is actively repressed in cultured skeletal muscle cells
and in regenerating adult skeletal muscle by factors that
binds GATA elements. Both mutation and deletion of
GATA elements in the cTnI promoter strongly up-regulate
promoter activity in skeletal muscle cells. In addition,
EMSA experiments show that 1) nuclear extracts of muscle
cells contain proteins that form specific complexes with
GATA elements present in the cTnI promoter, and 2) these
proteins do not correspond to GATA-2, -3 and -4, the only
GATA transcripts expressed in skeletal muscle cells. The
GATA-3 and -4 proteins are not detected and GATA-2 pro- tein is barely detected by Western blotting in skeletal muscle  cells. Figure 5
GATA-3 and -4 proteins are not detected and 
GATA-2 protein is barely detected by Western blot-
ting in skeletal muscle cells. Western blotting was per-
formed using antibodies specific for GATA-2, -3 or 4 and 
nuclear extracts of differentiated C2C12 cells (M) or control 
cells (He:Hela, J:Jurkat or H:heart cells). A control blot 
reacted with anti-MEF2 antibody demonstrates the presence 
of MEF2 in nuclear extracts of muscle cells. 20 µg of extract 
was loaded per lane.
He    M
MEF2
He    M
GATA-2 GATA-3
J     M
GATA-4
H M
Muscle cells express GATA-2, -3 and -4 but not GATA-1, -5  and -6 transcripts Figure 4
Muscle cells express GATA-2, -3 and -4 but not 
GATA-1, -5 and -6 transcripts. A. RT-PCR assays were 
performed with RNA preparations from differentiated 
C2C12 cells (M), using heart (H), liver (L) or brain (B) RNA 
preparations as positive controls. The primers used are indi-
cated in the Method section. Note that muscle cells express 
GATA-2, -3 and -4 but not GATA-1, -5 and -6 transcripts. B. 
Relative mRNA expression levels of GATA transcripts were 
evaluated by quantitative real-time PCR, using cyclophilin A 
as an internal standard.
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nature of the GATA-like factor(s) responsible for the
repression of the cTnI promoter in skeletal muscle cells
thus remains to be established.
A role of GATA elements in the regulation of skeletal mus-
cle gene promoters has been previously proposed. Muta-
tion of a GATA motif in the myosin light chain 3 promoter
was found to attenuate its activity in primary cultures of
neonatal rat skeletal muscle, however, the nature of the
factor(s) binding to this site was not determined [13].
Deletion of a GATA binding sequence in the dihydropyri-
dine-sensitive receptor (DHPR) α1 subunit promoter
leads to reduction in promoter activity and antisense
experiments for GATA-2 induced functional changes in L-
type calcium channels which are consistent with
decreased expression of α1 [16]. However, direct interac-
tion of GATA2 with DHPR promoter was not demon-
strated. An interaction between GATA factors and MyoD
in the regulation of the FGF4 gene promoter in embryonic
myotomes has also been described [17]. However, EMSA
assays were performed in HeLa cells and no evidence was
presented for the presence of GATA factors in the myo-
tomes. Thus direct evidence for the presence of GATA fac-
tors in nuclear extracts of skeletal muscle cells was not
reported in these studies.
GATA factors are best known as transcriptional activators
and inducers of cell differentiation. However, several
studies indicate that they can also act as transcriptional
repressors in different cell systems, including heart [18],
adipose tissue [19] and erythroid cells [20]. Proteins dis-
tinct from canonical GATA transcription factors can also
bind GATA elements and inhibit gene expression. The
ubiquitous nuclear DNA binding protein Ku70 was
shown to have a repressor activity in the transcriptional
regulation of the GBP and KEL promoters by binding
WGATAG, but not WGATAA elements [21,22]. However,
it is unlikely that Ku70 is responsible for the repression of
the cTnI promoter in skeletal muscle since all of the GATA
elements in the cTnI promoter have a GATAA consensus
sequence. GATA-like protein-1 (GPL-1), which is
expressed at high levels in the somatic cells of the devel-
oping gonads, but not in skeletal muscle, acts as a tran-
scriptional repressor of GATA factor function [23].
In conclusion, our results suggest that the transcription of
cTnI gene is actively repressed in skeletal muscle cells by
proteins binding to GATA motifs in the proximal pro-
moter. The finding that the transcription of the cTnI gene
promoter is actively repressed in skeletal muscle cells
raises the possibility that under certain conditions this
inhibitory mechanisms may be relieved and cTnI tran-
scription may take place also in skeletal muscle. Indeed,
cTnI mRNA has been detected in skeletal muscle biopsies
of patients with Duchenne muscular dystrophy at the
mRNA level [24] though not at the protein level [25].
Conclusion
The present study shows that cTnI promoter activity is
markedly increased in skeletal muscle by mutation or
deletion of GATA sites and that these sites form specific
complexes with proteins present in nuclear extracts of
muscle cells but different from canonical GATA factors.
Although the GATA-like factors involved in the repression
of the cTnI promoter have not yet been identified, our
results suggest a novel mechanism of repression of cardiac
promoters in skeletal muscle.
The cTnI GATA elements do not bind GATA-2, -3 and -4  protein in muscle cell nuclear extracts Figure 6
The cTnI GATA elements do not bind GATA-2, -3 
and -4 protein in muscle cell nuclear extracts. The 32P-
labeled cTnI GATA probe was incubated with C2C12 
nuclear extracts, Jurkat or cardiomyocyte nuclear extracts 
were used as controls. For supershift experiments, nuclear 
extracts were preincubated with anti-GATA-2, -3 or -4 anti-
body. In the presence of the anti-GATA-2 antibody, the 
major complex observed in the binding reaction of cTnI 
GATA probe with Jurkat nuclear extracts (arrow) is partially 
inhibited (compare lanes 1 and 2), while no inhibition is 
observed with the nuclear extract of C2C12 muscle cells 
(compare lanes 4 and 5). In the presence of the anti-GATA-3 
antibody, a supershift is observed with Jurkat nuclear extract 
(compare lanes 1 and 3), but no supershift is seen with 
C2C12 nuclear extract (compare lanes 4 and 6). A supershift 
is also observed with cardiomyocyte nuclear extract in the 
presence of the anti-GATA-4 antibody (compare lanes 7 and 
8), but no supershift is seen with C2C12 nuclear extracts 
(compare lanes 9 and 10).
GATA-2 Ab
Jurkat          C2C12 
1    2    3        4    5    6
- - + - - +
- + - - + - GATA-3 Ab GATA-4 Ab   - +    - +
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Methods
Plasmid constructs
The -230/+16 cTnI promoter linked to chloramphenicol
acetyl transferase (CAT) and the mutated constructs have
been described [4]. Deletion of the two GATA elements (-
67/-57) was obtained by double PCR as described [26].
Briefly, the cTnI promoter was amplified in two separate
reactions: from -230 to -67 and from -56 to +16 with the
oligos -67 and the -56 designed with a partial overlap.
Each PCR product was gel purified and combined in an
equimolar ratio. Three cycles without primers were per-
formed, and subsequently 20 cycles of PCR were per-
formed with addition of the 5'-upstream and 3'-
downstream primers. The final amplified product was
digested with HindIII and SalI and cloned into the plas-
mid pCAT enhancer (Promega). The construct was con-
firmed by sequencing.
Muscle regeneration and in vivo transfection
Male Wistar rats (200–250 g) were anesthetized with Iso-
flurane (FORANE, Abbott SpA) at 1–1.5% with oxygen.
The rat soleus muscle was exposed and muscle degenera-
tion/regeneration was induced by injecting 0.5% bupi-
vacaine (Marcaine) in saline solution. Intramuscular
injection of plasmid DNA (50 µg) was performed at day 3
after bupivacaine treatment as described previously [5].
Muscles were removed at 7 days after injury and frozen in
isopentane cooled in liquid nitrogen. Animals were kept
in conventional facilities with free access to food and
water. Adequate care for their health and well-being was
provided in accordance with the Italian Animal Act (Law
116/92). These studies were conducted under the supervi-
sion of the Institutional Ethics Committee.
Muscle cell cultures and transfections
Primary cultures of cardiac and skeletal muscle cells were
prepared from neonatal rat heart and hind limb muscles
as described previously [27]. Skeletal muscle cells were
grown for 3 days in DMEM supplemented with 20% fetal
calf serum, 2% glutamine and 12.5 U/ml penicillin-strep-
tomycin, then transfected with 10 µg of the cTnI-CAT con-
structs and 1 µg of CMV-lacZ, as an internal control. After
24 h, the cells were induced to differentiate by changing
the medium to DMEM supplemented with 4% horse
serum, 2% glutamine, 12.5 U/ml of penicillin-streptomy-
cin. The cultures were harvested after 2 days in the differ-
entiation medium. A similar procedure was used to obtain
differentiated cultured from C2C12 cells.
CAT assays
Muscles were homogenized in 200 µl ice-cold lysis solu-
tion containing 100 mM potassium phosphate pH 7.8,
0.1% triton and 1 mM dithiothreitol (added just before
use). Tissues were homogenized with an Ultra Turax T25.
The homogenates were centrifuged at 10.000 rpm for 30
min at 4°C; the supernatants were frozen in liquid nitro-
gen and stored at -80°C. CAT activity was assayed by TLC
scintillation counts as described [4]. Values (means ± S.E.)
were expressed as fold increase in CAT activity over the
promoterless construct. Each construct was tested in 4 to
8 independent experiments. For muscle cell cultures β-
Galactosidase and chloramphenicol acetyl transferase
(CAT) assays were performed with 25 µl of muscle cell
lysate. Values (means ± S.E.) were expressed as fold
increase in normalized CAT activity over the promoterless
construct. Each construct was tested in 3 to 5 independent
experiments.
Real-time RT-PCR
For real-time PCR assays, total RNA was prepared from
C2C12 myotubes with SV Total RNA Isolation reagent
(Promega). 400 ng of RNA was converted to cDNA using
random hexamers and Superscript II (Invitrogen). PCR
amplification was performed with an IQ5 real time PCR
system (BioRad) using SYBR green. The primers were
designed to span an intronic sequence and were validated
by PCR and gel analysis. Primer sequences were as follows
(forward & reverse):
GATA-1
F: 5' GCTCAGCAGCCTATTCTTCC 3'
R: 5' CGTTGCTCCACAGTTCACAC 3'
GATA-2
F: 5' ACGCCTGTGGCCTCTACTAC 3'
R: 5' GGATTTGCTGGACATCTTCC 3'
GATA-3
F: 5' ACCACGTCCCGTCCTACTAC 3'
R: 5' AGAGATCCGTGCAGCAGAG 3'
GATA-4
F: 5' CTGTCATCTCACTATGGGCAC 3'
R: 5' CCAAGTCCGAGCAGGAATTTG 3'
GATA-5
F: 5' TTTGAAGGCAGAGTCCAGTC 3'
R: 5' AGGCAAAGTCTTCAGGTTCG 3'
GATA-6BMC Molecular Biology 2007, 8:78 http://www.biomedcentral.com/1471-2199/8/78
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F: 5' TTCTACACAAGCGACCACCTC 3'
R: 5' GCCGTCTTGACCTGAATACTT 3'
The data were normalized using oligonucleotide primers
for cyclophilin A as an internal standard.
Western blotting
Nuclear extracts (20 µg) from C2C12 myotubes or other
cell types were separated by SDS-PAGE using 8% gels and
blots were incubated with monoclonal antibodies specific
for GATA-2, -3, -4 and a polyclonal antibody specific for
MEF2 (Santa Cruz Biotechnology Inc.). Antibody binding
was revealed by use of SuperSignal West Pico chemilumi-
nescent substrate (Pierce).
Gel Mobility Shift Assay
DNA/protein reactions and electrophoretic mobility shift
assays (EMSA) were performed as described [28] using 0.3
ng of cTnI GATA radiolabeled probe, 1 µg of poly
(dI·dC)-poly(dI·dC) (Amersham-Pharmacia Biotech)
and a 50–100-fold excess of competitor DNA. We used 2
µg of nuclear extracts from C2C12 muscle cells and either
Jurkat cells (Geneka) or cultured cardiomyocytes. Super-
shift assays were performed with antibodies specific for
GATA-2, -3 or -4 (Santa Cruz Biotechnology Inc.). The
antibodies were added to the DNA/nuclear extract mix,
and the binding was allowed to proceed for 1 hour before
loading the samples. The oligonucleotides used for these
experiments, including one specific for GATA sequences
from the BNP promoter [29], are listed in Table 1.
Data analysis
Data are expressed as means ± SE (represented as error
bars). Comparisons were made using the Student's t test,
considering P < 0.05 statistically significant.
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